Today, Xenetic Biosciences Inc Inc’s (NASDAQ: XBIO) stock fell $0.05, accounting for a 2.55% decrease. Xenetic opened at $1.96 before trading between $1.98 and $1.90 throughout Tuesday’s session. The activity saw Xenetic’s market cap fall to $18,534,344 on 246,706 shares -below their 30-day average of 889,434.
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.